Medical Policy and Coding Updates - October 2023
Summary
Effective October 1, 2023, Premera HMO added the Artificial Pancreas Device System with a closed-loop insulin delivery system (iLet Bionic pancreas), which may be considered medically necessary for individuals with type 1 diabetes, and made multimodal devices combining interferential current stimulation, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation investigational for all indications, including NexWave. Effective October 1, 2023, the gender transition and affirmation surgery policy added documentation that hair removal is intended to reduce gender dysphoria, changed the mental health recommendation timeframe from 6 to 12 months, and removed the prerequisite of hormone therapy for augmentation mammoplasty and genital surgeries. Effective October 1, 2023, Crysvita (burosumab) moved from the medical and pharmacy benefits to the medical benefit, and Elevidys (delandistrogene moxeparvovec-rokl) was added for ambulatory pediatric individuals aged 4 through 5 years with Duchenne muscular dystrophy and a confirmed DMD gene mutation.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.